Clinical Trials Directory

Trials / Conditions / Light Chain (AL) Amyloidosis

Light Chain (AL) Amyloidosis

11 registered clinical trials studyying Light Chain (AL) Amyloidosis — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
NCT07215494
Peking University First HospitalN/A
RecruitingDaratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Transl
NCT06629818
Peking Union Medical College HospitalPhase 2
RecruitingStudy of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
NCT06097832
Nexcella Inc.Phase 1 / Phase 2
WithdrawnVenetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (AL
NCT05486481
Alfred Chung, MDPhase 1 / Phase 2
Active Not RecruitingVenetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)
NCT05996406
Peking Union Medical College HospitalPhase 2
WithdrawnAn Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amylo
NCT05692908
Sorrento Therapeutics, Inc.Phase 1
RecruitingDaratumumab for Patients With Light Chain Amyloidosis
NCT06376214
Nanjing University School of MedicineN/A
WithdrawnIsatuximab and Bendamustine in Systemic Light Chain Amyloidosis
NCT04943302
Tufts Medical CenterPhase 2
TerminatedA Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
NCT04973137
Prothena Biosciences Ltd.Phase 3
UnknownStudy of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
NCT04316442
Sorrento Therapeutics, Inc.Phase 1 / Phase 2
CompletedA Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TA
NCT02015312
Florian MichelPhase 2